Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Galena Biopharma GALE

"Galena Biopharma is a biopharmaceutical company. Its main activity is the development and commercialization of hematology and oncology therapies. Its pipeline includes products targeting hematology diseases, breast cancer, gastric cancer, and gynecological cancer. The company’s cancer immunotherapy consists of two areas: prevention of cancer reoccurrence and primary prevention of invasive... see more

NDAQ:GALE - Post Discussion

Galena Biopharma > Galena Biopharma, Inc. (GALE) Pipeline Products Include Immu
View:
Post by MissionIR on Feb 03, 2014 6:58pm

Galena Biopharma, Inc. (GALE) Pipeline Products Include Immu

Galena Biopharma, Inc. (GALE) Pipeline Products Include Immunotherapy Cancer Treatments

Galena Biopharma is focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics.

Abstral, the Company’s sublingual formulation of fentanyl citrate, provides statistically significant and rapid relief of breakthrough cancer pain for patients with all types of cancer, providing improvements in pain-related daily function and patient quality of life. Currently in clinical trials, though, is NeuVax (neliepimut-S or E75), one of Galena’s cancer immunotherapy treatments.

The immunotherapy of cancer aims at specifically activating cells of the immune system, especially the so-called cytotoxic T-cells (“killer T-cells”) to seek out and eliminate tumor cells while not harming healthy tissue.

NeuVax works by turning on the immune system. It recruits the main components of the cellular immune system to fight cancer by presentation of a T-cell peptide epitope in the context of the peptide-HLA-T-cell receptor complex–effectively using the patient’s own immune system (i.e., nature’s own defense system against foreign or harmful germs) for the treatment of the cancer.

Folate Binding Protein-E39 (FBP), another Galena treatment, is a targeted vaccine aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. It has very limited tissue distribution and expression in non-malignant tissue making it an ideal immunotherapy target.

The FBP vaccine consists of the E39 peptide derived from the folate binding protein combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF), and is specifically used to treat endometrial and ovarian cancers.

Ideally, a vaccine is specific and should only affect the cancer cells and not attack normal cells. Cancer immunotherapy causes the immune system to make antibodies to one or several specific antigens, and/or make killer T cells to attack cancer cells that express those antigens. Similar to prophylactic vaccines, Galena’s cancer immunotherapies can be delivered with adjuvants, which are designed to boost the immune response.

For more information, visit the website at www.galenabiopharma.com

Please read full disclaimers at https://disclaimer.missionir.com

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities